Clavulanic acid (CA) is an important pharmaceutical compound produced by batch fermentation of Streptomyces clavuligerus. Since, CA is chemically unstable, its downstream processing should be studied to develop more efficient and resolute techniques. Herein, the use of aqueous two-phase systems (ATPS) composed of cholinium chloride, [Ch]Cl, was proposed as a novel platform for the recovery and purification of CA. Thus, the stability of CA in presence of different [Ch]Cl concentrations was initially studied, and the high biocompatibility of this salt was demonstrated by the low CA degradation levels. Then, the partitioning of CA using two types of polymeric ATPS has been investigated. Two ATPS formed by the combination of [Ch]Cl and two polyethylene glycol (PEG) polymers, PEG 600 g mol À1 (PEG-600) and polyethylene glycol methyl ether 550 g mol À1 (PEG-500-OMe), were used to assess the influence of the PEG nature, in addition to the concentration of the phase forming agents on the CA partitioning. It has shown that CA is almost equally distributed between the two-phases in equilibrium (0.6 < K CA < 1.6). Nevertheless, the selective extraction of CA for the [Ch]Cl-rich or PEG-rich phase by the proper adjustment of ATPS composition was attained. In the search for higher extraction efficiencies [EE (%)] and partition coefficients (K CA), a second polymeric ATPS platform composed of PEG-600 and sodium polyacrylate 8000 g mol À1 (NaPA-8000), applying [Ch]Cl as adjuvant was tested. The main results suggest the recovery of CA towards the PEG-rich phase (K CA ! 5.6 ± 0.6 and EE ! 85.5± 1.4%). The higher migration levels of CA have mainly resulted from the electronegative repulsion of NaPA-8000 over CA molecules. The ATPS with best performance for the CA extraction were selected for the recovery of CA directly from fermented broth of Streptomyces clavuligerus. In this set of experiments, the highest values of CA recovery yield and purification factor (respectively, 64.91± 1.99% and 22.70 ± 0.87) were attained for the systems PEG-600/NaPA-8000 and PEG-600/[Ch]Cl, respectively.
Carbamazepine (CBZ) is a representative of a group of compounds found in our rivers that have been classified as upcoming contaminants. Its pharmacological activity to treat mood and neurological disorders is based on its effects on ion channels, but effects on aquatic organisms have not yet been thoroughly investigated.In our initial analysis, we compared CBZ effects on two microalgae species differing in CBZ sensitivity: Parachlorella kessleri and Neochloris pseudoalveolaris. While we observed a stimulation in the growth rate in cultures of P. kessleri in the presence of 10 μg L −1 CBZ, no effect on growth rates of N. pseudoalveolaris cultures could be documented at this concentration. Any higher tested CBZ concentration led to growth inhibition.To gain insight into these effects, biochemical and physiological parameters of these two microalgae species were measured in the presence of CBZ in a concentration-dependent manner.As the severe inhibition of growth rate correlated with a significant inhibition of most tested parameters in cultures of N. pseudoalveolaris, the primary reason for the adverse effect of CBZ on cultures of this microalgae species could not be identified. In cultures of N. pseudoalveolaris, experimental data indicate that inhibition of growth rate occurs when the microalgae are no longer able to compensate for adverse CBZ-induced ROS effects.Analysis of the CBZ response of cultures of P. kessleri showed a reduction of growth stimulatory effect if the CBZ concentration exceeds a threshold value. In general, cultures of P. kessleri show a great potential to withstand CBZ as an environmental pollutant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.